TR200402628T4 - Androjenetik ve yaygın alopezinin tedavisinde melatonin maddesinin kullanımı - Google Patents

Androjenetik ve yaygın alopezinin tedavisinde melatonin maddesinin kullanımı

Info

Publication number
TR200402628T4
TR200402628T4 TR2004/02628T TR200402628T TR200402628T4 TR 200402628 T4 TR200402628 T4 TR 200402628T4 TR 2004/02628 T TR2004/02628 T TR 2004/02628T TR 200402628 T TR200402628 T TR 200402628T TR 200402628 T4 TR200402628 T4 TR 200402628T4
Authority
TR
Turkey
Prior art keywords
melatonin
treatment
androgenetic
diffuse alopecia
alopecia
Prior art date
Application number
TR2004/02628T
Other languages
English (en)
Turkish (tr)
Inventor
Elsner Peter
Original Assignee
Asat Ag Applied Science & Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asat Ag Applied Science & Technology filed Critical Asat Ag Applied Science & Technology
Publication of TR200402628T4 publication Critical patent/TR200402628T4/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Birds (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TR2004/02628T 1999-11-30 2000-11-29 Androjenetik ve yaygın alopezinin tedavisinde melatonin maddesinin kullanımı TR200402628T4 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19957710A DE19957710A1 (de) 1999-11-30 1999-11-30 Verwendung von Melatonin zur Behandlung der androgenetischen Alopezie
US09/506,442 US6281241B1 (en) 1999-11-30 2000-02-18 Use of melatonin for the treatment of androgenetic alopecia

Publications (1)

Publication Number Publication Date
TR200402628T4 true TR200402628T4 (tr) 2004-11-22

Family

ID=7930930

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2004/02628T TR200402628T4 (tr) 1999-11-30 2000-11-29 Androjenetik ve yaygın alopezinin tedavisinde melatonin maddesinin kullanımı

Country Status (12)

Country Link
US (2) US6281241B1 (cg-RX-API-DMAC10.html)
EP (1) EP1235571B1 (cg-RX-API-DMAC10.html)
JP (1) JP4713805B2 (cg-RX-API-DMAC10.html)
AT (1) ATE275400T1 (cg-RX-API-DMAC10.html)
AU (1) AU2838101A (cg-RX-API-DMAC10.html)
CA (1) CA2392620C (cg-RX-API-DMAC10.html)
DE (2) DE19957710A1 (cg-RX-API-DMAC10.html)
DK (1) DK1235571T3 (cg-RX-API-DMAC10.html)
ES (1) ES2228663T3 (cg-RX-API-DMAC10.html)
PT (1) PT1235571E (cg-RX-API-DMAC10.html)
TR (1) TR200402628T4 (cg-RX-API-DMAC10.html)
WO (1) WO2001039771A1 (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19957710A1 (de) * 1999-11-30 2001-05-31 Asat Ag Applied Science & Tech Verwendung von Melatonin zur Behandlung der androgenetischen Alopezie
US7015072B2 (en) 2001-07-11 2006-03-21 Asat Limited Method of manufacturing an enhanced thermal dissipation integrated circuit package
US6734552B2 (en) 2001-07-11 2004-05-11 Asat Limited Enhanced thermal dissipation integrated circuit package
US6790710B2 (en) 2002-01-31 2004-09-14 Asat Limited Method of manufacturing an integrated circuit package
US20030178719A1 (en) * 2002-03-22 2003-09-25 Combs Edward G. Enhanced thermal dissipation integrated circuit package and method of manufacturing enhanced thermal dissipation integrated circuit package
US6940154B2 (en) * 2002-06-24 2005-09-06 Asat Limited Integrated circuit package and method of manufacturing the integrated circuit package
DK1562585T3 (da) * 2002-10-30 2011-03-14 Asat Ag Applied Science & Tech Daglige melatonindoseringsenheder
CN1708331A (zh) * 2002-10-30 2005-12-14 Asat应用科学技术股份公司 含有褪黑素、银杏和生物素的制剂
US20050249785A1 (en) * 2003-08-13 2005-11-10 Gordon John G Use of melatonin-containing oral supplement with animals
MXPA06009377A (es) * 2004-02-20 2007-03-07 Lifescape Biosciences Inc Composiciones y metodos para regulacion del sueno.
JP3964417B2 (ja) * 2004-09-27 2007-08-22 国立大学法人金沢大学 インドール誘導体を有効成分とするα２受容体遮断剤及び血管拡張剤
US20080059313A1 (en) * 2006-08-30 2008-03-06 Oblong John E Hair care compositions, methods, and articles of commerce that can increase the appearance of thicker and fuller hair
ITGE20070009A1 (it) * 2007-01-24 2008-07-25 Leila Baeram Composizione cosmetica e metodo per favorire la ricrescita dei capelli.
US20100120871A1 (en) * 2008-11-10 2010-05-13 Dawson Jr Thomas Larry Hair care compositions, methods, and articles of commerce that can increase the appearance of thicker and fuller hair
GB0918564D0 (en) 2009-10-22 2009-12-09 Plasticell Ltd Nested cell encapsulation
WO2011109459A2 (en) * 2010-03-04 2011-09-09 University Of Miami Compositions, kits and methods for determining efficacy of a therapeutic agent and treating hair and skin diseases
ITMI20112432A1 (it) * 2011-12-30 2013-07-01 Bionest Ltd Kit per il trattamento e la prevenzione dell'alopecia
WO2015176161A1 (en) 2014-05-23 2015-11-26 Triple Hair Inc. Compositions for reducing hair loss and/or increasing hair regrowth
US11696883B2 (en) 2014-05-23 2023-07-11 Triple Hair Inc. Compositions for reducing hair loss and/or increasing hair regrowth
WO2016166047A1 (en) 2015-04-14 2016-10-20 Phyture Biotech, S.L. Cell-free plant cell culture suspension supernatant with re-youth activity and/or wound healing activity over skin cells
US10039703B2 (en) 2015-07-08 2018-08-07 Triple Hair Inc. Composition comprising resveratrol and melatonin for reducing hair loss and/or increasing hair regrowth
JP7118425B2 (ja) 2016-04-11 2022-08-16 バイチュラス バイオテック，ソシエダ リミタダ 脱毛の予防及び／又は治療のためのペプチド及び医薬組成物、栄養補助組成物、又は獣医学組成物
GB201707143D0 (en) 2017-05-04 2017-06-21 Plasticell Ltd Method for producing cells
GB2638109A (en) * 2022-06-20 2025-08-20 John Hemming Trading Ltd Cell differentiation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340579A (en) * 1984-11-20 1994-08-23 Farmaka S.R.L. Method of treating dermatological conditions
US4746674A (en) 1985-08-27 1988-05-24 Cellena (Cell Engineering) Ag Melatonin compositions and uses thereof
JPS61212512A (ja) * 1985-03-19 1986-09-20 Shiseido Co Ltd 養毛料
US4945103A (en) * 1989-01-17 1990-07-31 Michael Cohen Method of treating pre-menstrual syndrome
FR2717381B1 (fr) * 1994-03-15 1996-04-19 Oreal Compositions à base d'alpha-pyrones pour induire et stimuler la croissance des cheveux et/ou freiner leur chute et utilisation.
JP3108586B2 (ja) * 1994-06-01 2000-11-13 富士産業株式会社 育毛剤
US5597575A (en) * 1994-06-06 1997-01-28 Breitbarth; Richard Composition for stimulating and inducing hair growth
DE19509354A1 (de) * 1994-12-08 1996-06-13 Klett Loch Lore M Kombinationspräparat zur Förderung des Haarwachstums und ggf. des Haut- und Nagelwachstums sowie zur Verhinderung bzw. zur Beseitigung von Haarausfall
US5792785A (en) * 1995-11-24 1998-08-11 Equitech Laboratories, Inc. Method for enhancing pregnancy success in an animal
ES2101660B1 (es) * 1995-12-21 1997-12-16 Soler Armando Jose Yanez Nuevo crecepelo de uso topico.
GB2314019B (en) * 1996-06-10 2000-03-15 Bio Scient Ltd The use of L-Lysine in the treatment of hair loss
FR2751539B1 (fr) * 1996-07-25 1998-12-04 Oreal Nouvelles compositions topiques comprenant de tres faibles doses de melatonine ou ses derives et leur utilisation en cosmetique
WO1998005298A1 (es) * 1996-08-02 1998-02-12 Universidad De Granada Desarrollo de productos cosmeticos para uso humano a base de melatonina como producto activo
FR2754454B1 (fr) * 1996-10-10 1998-11-27 Oreal Utilisation d'au moins un glycol comme agent de solubilisation de la melatonine dans l'eau et compositions obtenues
FR2756832B1 (fr) * 1996-12-06 1999-01-08 Oreal Utilisation de melatonine dans une composition pour stabiliser les polymeres gelifiants hydrophiles
US5958964A (en) * 1997-02-18 1999-09-28 South Alabama Medical Science Foundation Use of melatonin to prevent cytotoxic effects of amyloid beta protein
US6030948A (en) * 1997-12-19 2000-02-29 Mann; Morris A. Hair regeneration compositions for treatment of alopecia and methods of application related thereto
US6274615B1 (en) * 1998-03-25 2001-08-14 South Alabama Medical Science Foundation Method for delaying the onset of alheimer's disease and for treatment or delaying the onset of other amyloidosis-related diseases/disorders
DE19957710A1 (de) * 1999-11-30 2001-05-31 Asat Ag Applied Science & Tech Verwendung von Melatonin zur Behandlung der androgenetischen Alopezie
US6747008B1 (en) * 2000-06-19 2004-06-08 University Of Southern California Methods for treating and preventing alopecia
FR2811550B1 (fr) * 2000-07-11 2003-02-14 Oreal Composition a base de vitamines et de sels mineraux, pour diminuer la chute des cheveux et/ou favoriser la repousse des cheveux

Also Published As

Publication number Publication date
ES2228663T3 (es) 2005-04-16
WO2001039771A1 (de) 2001-06-07
DE50007706D1 (de) 2004-10-14
PT1235571E (pt) 2004-12-31
EP1235571B1 (de) 2004-09-08
CA2392620C (en) 2009-10-13
JP2004500353A (ja) 2004-01-08
JP4713805B2 (ja) 2011-06-29
US20020183377A1 (en) 2002-12-05
US6281241B1 (en) 2001-08-28
ATE275400T1 (de) 2004-09-15
CA2392620A1 (en) 2001-06-07
DK1235571T3 (da) 2005-01-17
EP1235571A1 (de) 2002-09-04
DE19957710A1 (de) 2001-05-31
AU2838101A (en) 2001-06-12

Similar Documents

Publication Publication Date Title
NO20014303D0 (no) JAK-3-inhibitorer for behandling av allergiske lidelser
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
DK1235571T3 (da) Anvendelse af melatonin til behandling af androgenetisk eller diffus alopecia af feminin type
CY1115521T1 (el) Σχηματισμοi οι οποiοι περιλαμβανουν αντι-κωδικευσης νουκλεοτιδια σε συνδετινες
DE60234269D1 (de) Substituierte aryl 1,4-pyrazin derivate
DE60031248D1 (de) Elektroaktive pore
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
TR200200821T2 (tr) 5-Beta-sapojenin ve pseudosapojenin türevleri ve bunların bunama tedavisinde kullanımı.
HRP20020593B1 (hr) Liječenje ozljeda mozga, kralježnične moždine i živca
ID30116A (id) Turunan-turunan piridopiranoazepin, pembuatannya dan penggunaan terapinya
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
NO20004419D0 (no) Ny anvendelse
SE9904377D0 (sv) Pharmaceutical combinations
CY1106409T1 (el) Παραγωγα κινολινης
DK0855916T3 (da) Farmaceutisk præparat indeholdende en Activin-stimulator
ATE317849T1 (de) 5-hydroxysapogenin derivate mit aktivität gegen demenz
IS7492A (is) Lyfjablöndu uppskriftir, sem innifela melantónín
DE69604071D1 (de) Oxazolidinone derivate, ihre herstellung und ihre therapeutische verwendung
TR200102512T2 (tr) Tüm ruhsal bozukluklar, adaptasyon bozuklukları ve çeşitli kaygı-depresyon bozukluklarının tedavisinde ya da önlenmesinde yararlı tıbbi ürünlerin hazırlanması için saredutan ve onun farmasötik olarak kabul edilebilir tuzlarının kullanımı.
HUP0203153A2 (hu) Kombinációs kemoterápia
BR0015938A (pt) Uso de antagonistas beta-adrenoceptores para a fabricação de um medicamento para o tratamento de desordens da retina externa
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
UA85187C2 (en) 2-aminobenzoyl derivatives